Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies
Brett M. Stevens(University of Rochester), Daniel A. Pollyea(University of Colorado Denver), Craig T. Jordan(University of Colorado Anschutz Medical Campus), Jonathan A. Gutman(University of Colorado Denver), Olivia J. Ondracek(University of Colorado Anschutz Medical Campus), Maria L. Amaya(University of Colorado Denver), Connor Adkins(University of Colorado Anschutz Medical Campus), Christine M. McMahon(Albert Einstein College of Medicine), Clayton A. Smith(University of Colorado Anschutz Medical Campus), Amanda Winters(University of Colorado Denver), Deng Wang(Ezhou Central Hospital), Mohammad Minhajuddin(University of Colorado Denver)
Cited by 0
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells
|Blood|2005|675
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
|Cancer Cell|2018|565